Polymorphs of nek 7 inhibitors
Patent Information
- Application Number
- HK62026127131
- Authority / Receiving Office
- HK · HK
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2023-05-26
- Filing Date
- 2026-08-06
- Publication Date
- 2026-09-11
Smart Images

Figure 00000000_0000_ABST
Abstract
Description
This disclosure relates to the solid form of a compound having structural formula (I) or its tautomers. This disclosure also relates to methods for preparing and using the solid form of the compound having structural formula (I). Abstract
Claims
CLAIMS 1. A solid form of a compound having the following Structure (I):or a tautomer thereof, wherein the solid form has an X-ray powder diffraction pattern with peaks at 2-theta angles selected from at least two of 7.33 ± 0.2°, 10.51 ± 0.2°, 15.93 ± 0.2°, and 18.92 ± 0.2°.
2. The solid form of claim 1, wherein the solid form has an X-ray powder diffraction pattern with peaks at 2-theta angles selected from at least three of 7.33 ± 0.2°, 10.51 ± 0.2°, 15.93 ± 0.2°, and 18.92 ± 0.2°.
3. The solid form of claim 1, wherein the solid form has an X-ray powder diffraction pattern with peaks at 2-theta angles at 7.33 ± 0.2°, 10.51 ± 0.2°, 15.93 ± 0.2°, and 18.92 ± 0.2°.
4. The solid form of claim 1, wherein the solid form has an X-ray powder diffraction pattern with peaks at 2-theta angles selected from at least two of 7.33°, 10.51°, 15.93°, and 18.92°.
5. The solid form of claim 1, wherein the solid form has an X-ray powder diffraction pattern with peaks at 2-theta angles selected from at least three of 7.33°, 10.51°, 15.93°, and 18.92°.
6. The solid form of claim 1, wherein the solid form has an X-ray powder diffraction pattern with peaks at 2-theta angles at 7.33°, 10.51°, 15.93°, and 18.92°.
7. The solid form of claim 1, wherein the solid form has an X-ray powder diffraction pattern with peaks at 2-theta angles at 3.87 ± 0.2°, 7.73 ± 0.2°, 10.51 ± 0.2°, 12.71 ± 0.2°, 13.53 ± 0.2°, 13.99 ± 0.2°, 15.93 ± 0.2°, 18.92 ± 0.2°, 21.56 ± 0.2°, 22.74 ± 0.2°, 23.19 ± 0.2°, 24.53 ± 0.2°, 25.63 ± 0.2°, 27.73 ± 0.2°, 31.17 ± 0.2°, and 36.49 ± 0.2°.
8. The solid form of claim 1, wherein the solid form has an X-ray powder diffraction pattern with peaks at 2-theta angles at 3.87°, 7.73°, 10.51°, 12.71°, 13.53°, 13.99°, 15.93°, 18.92°, 21.56°, 22.74°, 23.19°, 24.53°, 25.63°, 27.73°, 31.17°, and 36.49°.
9. The solid form of claim 1, wherein the solid form comprises solid form Type B.
10. The solid form of claim 1, wherein the solid form consists essentially of solid form Type B.
11. The solid form of claim 1, wherein the solid form is substantially pure.
12. A solid form of a compound having the following Structure (I):or a tautomer thereof, having an X-ray powder diffraction pattern substantially in accordance with that depicted in FIG.
56.
13. The solid form of any one of claims 1-12, characterized by a differential scanning calorimetry thermogram comprising an endothermic peak at 205.7°C ± 0.5°C.
14. The solid form of claim 13, wherein the endothermic peak is greater than 100 J / g.
15. The solid form of claim 13, wherein the endothermic peak is greater than 115 J / g.
16. The solid form of any one of claims 1-15, characterized by a differential scanning calorimetry thermogram substantially in accordance with that depicted in FIG.
8.
17. A solid form of a compound having the following Structure (I):or a tautomer thereof, wherein the solid form has an X-ray powder diffraction pattern with peaks at 2-theta angles selected from at least two of 4.67 ± 0.2°, 9.35 ± 0.2°, 25.49 ± 0.2°, and 26.93 ± 0.2°.
18. The solid form of claim 17, wherein the solid form has an X-ray powder diffraction pattern with peaks at 2-theta angles at 4.67 ± 0.2°, 9.35 ± 0.2°, 25.49 ± 0.2°, and 26.93 ± 0.2°.
19. The solid form of claim 17, wherein the solid form has an X-ray powder diffraction pattern with peaks at 2-theta angles selected from at least two of 4.67°, 9.35°, 25.49°, and 26.93°.
20. The solid form of claim 17, wherein the solid form has an X-ray powder diffraction pattern with peaks at 2-theta angles at 4.67°, 9.35°, 25.49°, and 26.93°.
21. The solid form of claim 17, wherein the solid form has an X-ray powder diffraction pattern with peaks at 2-theta angles at 4.67 ± 0.2°, 5.41 ± 0.2°, 9.35 ± 0.2°, 11.32 ± 0.2°, 13.49 ± 0.2°, 15.35 ± 0.2°, 17.15 ± 0.2°, 18.73 ± 0.2°, 20.57 ± 0.2°, 22.87 ± 0.2°, 24.27 ± 0.2°, 25.49 ± 0.2°, 26.93 ± 0.2°, and 29.97 ± 0.2°.
22. The solid form of claim 17, wherein the solid form has an X-ray powder diffraction pattern with peaks at 2-theta angles at 4.67°, 5.41°, 9.35°, 11.32°, 13.49°, 15.35°, 17.15°, 18.73°, 20.57°, 22.87°, 24.27°, 25.49°, 26.93°, and 29.97°.
23. The solid form of claim 17, wherein the solid form comprises solid form Type Q.
24. The solid form of claim 17, wherein the solid form consists essentially of solid form Type Q.
25. The solid form of claim 17, wherein the solid form is substantially pure.
26. A solid form of a compound having the following Structure (I):or a tautomer thereof, having an X-ray powder diffraction pattern substantially in accordance with that depicted in FIG.
57.
27. The solid form of any one of claims 17-26, characterized by a differential scanning calorimetry thermogram comprising endothermic peak at 217.0°C ± 0.5°C.
28. The solid form of any one of claims 17-27, characterized by a differential scanning calorimetry thermogram substantially in accordance with that depicted in FIG.
47.
29. A composition comprising the solid form of any one of claims 1-16 and the solid form for any one of claims 17-28.
30. A pharmaceutical composition comprising a solid form of any one of claims 1-28 and a pharmaceutically acceptable carrier or excipient.
31. The pharmaceutical composition of claim 30, formulated for oral administration.
32. The pharmaceutical composition of claim 30, in the form of a capsule.
33. The pharmaceutical composition of claim 30, in the form of a tablet.
34. A method of treating a NLRP3-mediated disorder, comprising administering a therapeutically effective amount of a solid form of any one of claims 1-28, or a composition of any one of claims 29-33, to a subject in need thereof.
35. The method of claim 34, wherein the disorder is selected from auto-immune, inflammatory disorders, cardiovascular diseases, neurodegenerative disorders, bacterial and viral infections, allergy, asthma, pancreatitis, multi-organ failure, kidney diseases, platelet aggregation, cancer, transplantation, sperm motility, erythrocyte deficiency, graft rejection, lung injuries, respiratory diseases, and ischemic conditions.
36. The method of claim 34 or 35, wherein the disorder is selected from type II diabetes, atherosclerosis, Alzheimer's disease, aging, fatty liver, metabolic syndrome, asthma, psoriasis, obesity, acute and chronic tissue damage caused by infection, gout, arthritis, macular degeneration, enteritis, hepatitis, peritonitis, silicosis, UV-induced skin sunburn, contact hypersensitivity, sepsis, cancer, neurodegenerative disease, multiple sclerosis, Muckle-Wells syndrome, and myelodysplastic syndrome (MDS).
